Adam Zong, PHD, MBA
Consultant
Biopharma executive and entrepreneur with global leadership experience in strategic partnerships and portfolio innovation
Dr. Zong is a seasoned biopharma executive and entrepreneur with over two decades of leadership experience spanning global pharma and biotech. He brings deep expertise in corporate and portfolio strategy, business development and licensing (BD&L), M&A, and product innovation across oncology, hematology, immunology, and cardiometabolic diseases.
As founding CEO of Hengrui Therapeutics (US) and President & COO of Seven & Eight Biopharma, he built and led both companies from inception through multiple funding rounds and strategic partnerships with Merck and Roche, advancing assets through clinical milestones and successful out-licensing transactions. Earlier, he held senior leadership roles at Merck, Bristol Myers Squibb, Schering-Plough, and Pfizer—driving global oncology and hematology portfolios, leading over 300 strategic transactions exceeding $30 billion in value, and contributing to the development and commercialization of transformative therapies including Keytruda® and Opdivo®. Dr. Zong earned his Ph.D. in Oncology/Virology from The Rockefeller University, his MBA from The Wharton School, and his B.S. in Genetic Engineering from Fudan University.
